Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_2:p12
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 2 (pt 12/13)
Character Range: 17507552–17510469

must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).
V16000          Fentanyl                   Authorities for increased maximum quantities and/or repeats must only be considered for chronic severe disabling pain where the patient has received initial authority approval and the total duration of non-PBS and PBS opioid analgesic treatment: (i) is less than 12 months; or (ii) exceeds 12 months and the palliative care patient is unable to have annual pain management review due to their clinical condition; or (iii) exceeds 12 months and the patient's clinical need for continuing opioid treatment has been confirmed through consultation with the patient by another medical practitioner or a palliative care nurse practitioner in the past 12 months; or (iv) has exceeded 12 months prior to 1 June 2020 and the patient's pain management and clinical need for continuing opioid treatment has not been confirmed through consultation with the patient by another medical practitioner or a palliative care nurse practitioner in the past 12 months, but is planned in the next 3 months.
                Methadone                  Authority requests extending treatment duration up to 1 month may be requested through the Online PBS Authorities system or by calling Services Australia. Authority requests extending treatment duration beyond 1 month may be requested through the Online PBS Authorities system or in writing and must not provide a treatment duration exceeding 3 months (quantity sufficient for up to 1 month treatment and sufficient repeats).

National Health (Listing of Pharmaceutical Benefits) Instrument 2024

PB 26 of 2024
made under sections 84AF, 84AK, 85, 85A and 88 of the

National Health Act 1953

Compilation No. 10

Compilation date: 1 February 2025

                Includes amendments: F2025L00062

This compilation is in 10 volumes

Volume 1: sections 1–24 and Schedule 1 (Part 1: A–C)
Volume 2: Schedule 1 (Part 1: D–K)
Volume 3: Schedule 1 (Part 1: L–P)
Volume 4: Schedule 1 (Part 1: Q–Z, Part 2), Schedules 2 and 3
Volume 5: Schedule 4 (Part 1: C4076–C9993)
Volume 6: Schedule 4 (Part 1: C10020–C12999)
Volume 7: Schedule 4 (Part 1: C13006–C13925)
Volume 8: Schedule 4 (Part 1: C13927–C14567)
Volume 9: Schedule 4 (Part 1: C14568–C16290, Part 2)
Volume 10: Schedules 5, 6 and Endnotes

Each volume has its own contents

About this compilation

This compilation

This is a compilation of the National Health (Listing of Pharmaceutical Benefits) Instrument 2024 that shows the text of the law as amended and in force on 1 February 2025 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text